Related Experiment Video
Updated: Apr 30, 2026
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
The Development of Chemical Probes for Targeting Coactivator Associated Arginine Methyltransferase 1 (CARM1)
Kadalipura P Rakesh1, Santosh Kumar Verma2, Man Vir Singh3
1Department of Radiology, Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Abstract:
As a transcriptional coactivator and associated arginine methyltransferase 1, CARM1 controls various biological functions. CARM1 was thought to be a prospective therapeutic target, as anomalous appearance of the gene has been linked to the development of several cancer types. Since there aren't any CARM1 inhibitors available for use in clinical trials at the moment, Kindle is interested in the development of human pharmacological treatments that target CARM1. To confirm this PRMT as a therapeutic target, selective inhibitors of CARM1 would be helpful tools. In this review, we discuss the identification, description, and biological use of CARM1 inhibitors, focusing on significant developments in the field.
Insights
Selective inhibitors targeting CARM1 (coactivator-associated arginine methyltransferase 1) are crucial for cancer therapy development. This review highlights key advancements in identifying and utilizing these potential CARM1-targeted drugs.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Coactivator-associated arginine methyltransferase 1 (CARM1) functions as a transcriptional coactivator and plays a role in various biological processes.
- Aberrant CARM1 expression is implicated in the pathogenesis of multiple cancer types, positioning it as a potential therapeutic target.
- Currently, no CARM1 inhibitors are available for clinical use, necessitating research into their development.
Purpose of the Study:
- To review the identification, characterization, and biological applications of CARM1 inhibitors.
- To highlight significant progress in the development of selective CARM1 inhibitors for potential therapeutic use.
- To underscore the importance of CARM1 inhibitors in validating CARM1 as a drug target for cancer treatment.
Main Methods:
- Literature review of published studies on CARM1 inhibitors.
- Analysis of the identification and description of various CARM1 inhibitors.
- Evaluation of the biological roles and therapeutic potential of CARM1 inhibitors.
Main Results:
- Several CARM1 inhibitors have been identified and described.
- These inhibitors demonstrate potential for targeting CARM1 in biological systems.
- The development of selective inhibitors is crucial for further research and clinical application.
Conclusions:
- CARM1 is a promising therapeutic target for cancer treatment.
- Selective CARM1 inhibitors are essential tools for confirming its therapeutic validity.
- Continued research into CARM1 inhibitors is vital for advancing pharmacological treatments for cancer.
More Related Videos
16:16Genetically-encoded Molecular Probes to Study G Protein-coupled Receptors
Published on: September 13, 2013
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
